search
Back to results

Peripheral Microvascular Resistance as a Predictor for Limb Salvage

Primary Purpose

Peripheral Arterial Disease

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Peripheral vascular flow reserve measurement
Sponsored by
Hackensack Meridian Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Peripheral Arterial Disease focused on measuring Microvascular disease, Microvascular Resistance, Limb Salvage, Peripheral Arterial Disease, critical limb ischemia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Chronic critical limb ischemia (Rutherford 4-6). Age ≥18 years Ability and willingness to sign the IRB approved Informed Consent form Exclusion Criteria: Non-reconstructable chronic total occlusive disease of the proximal inflow vessels that would make flow reserve measurements impossible. Non-salvageable lower extremity due to infection or overwhelming per-existing tissue loss (most critical Rutherford 6 patients). Inability to understand the study or a history of non-compliance with medical advice; History of any cognitive or mental health status that would interfere with study participation; Currently enrolled in any pre-approval investigational study. Female subjects who are pregnant or nursing or planning to become pregnant within the study period; Known sensitivity to contrast media, which can't be adequately pre-medicated; Expected life span less than 6 months. Unable to read/understand/sign the English Language consent form

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Peripheral vascular flow reserve measurement

    Arm Description

    Post-procedure peripheral vascular flow reserve by thermodilution will be measured by the pressure wire.

    Outcomes

    Primary Outcome Measures

    Efficacy of the peripheral flow reserve
    To assess whether peripheral flow reserve can predict the success rate of limb salvage in critical limb ischemia patients after endovascular intervention. Assessed by any amputation (major or minor) at 6 months post-endovascular intervention.

    Secondary Outcome Measures

    Symptom resolution - Ulcer healing (1m)
    Ulcer healing: changes in the number and extent of leg ulcers compared to baseline.
    Symptom resolution - Ulcer healing (6m)
    Ulcer healing: changes in the number and extent of leg ulcers compared to baseline.
    Number of patients with Symptom resolution - Pain (1m)
    Resolution of rest pain and alteration in visual analogue pain compared to baseline.
    Number of patients with Symptom resolution - Pain (6m)
    Resolution of rest pain and alteration in visual analogue pain compared to baseline.
    Ankle-brachial index (ABI) (1m)
    Improvement in Ankle-brachial index (ABI) compared to baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. Normal ABI ranges from 1.0 - 1.4, with <0.9 suggesting arterial disease.
    Ankle-brachial index (ABI) (6m)
    Improvement in Ankle-brachial index (ABI) compared to baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. Normal ABI ranges from 1.0 - 1.4, with <0.9 suggesting arterial disease.
    Toe-brachial index (TBI) (1m)
    Improvement in Toe-brachial index (TBI) compared to baseline. The Toe Brachial Index (TBI) is defined as the ratio between the systolic blood pressure in the right or left toe and the higher of the systolic pressure in the right or left arms. TBI ≥ 0.7 is considered normal while TBI < 0.7 is considered abnormal.
    Toe-brachial index (TBI) (6m)
    Improvement in Toe-brachial index (TBI) compared to baseline. The Toe Brachial Index (TBI) is defined as the ratio between the systolic blood pressure in the right or left toe and the higher of the systolic pressure in the right or left arms. TBI ≥ 0.7 is considered normal while TBI < 0.7 is considered abnormal.
    Rutherford classification (1m)
    Use of The Rutherford classification to assess peripheral artery disease compared to baseline. A 7 category scale is being used with 0 being Asymptomatic and 6 being Ulceration or gangrene.
    Rutherford classification (6m)
    Use of The Rutherford classification to assess peripheral artery disease compared to baseline. A 7 category scale is being used with 0 being Asymptomatic and 6 being Ulceration or gangrene.
    Transcutaneous oxygen partial pressure (TcPO2) (1m)
    Transcutaneous partial pressure of oxygen (TcPO2) will be measured representing the amount of oxygen diffusing outward across the skin (used as a surrogate for arterial perfusion).
    Transcutaneous oxygen partial pressure (TcPO2) (6m)
    Transcutaneous partial pressure of oxygen (TcPO2) will be measured representing the amount of oxygen diffusing outward across the skin (used as a surrogate for arterial perfusion).
    Target lesion revascularization (1m)
    Need for revascularization (yes/no)
    Target lesion revascularization (6m)
    Need for revascularization (yes/no)

    Full Information

    First Posted
    August 21, 2023
    Last Updated
    September 20, 2023
    Sponsor
    Hackensack Meridian Health
    Collaborators
    Abbott Medical Devices
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06014242
    Brief Title
    Peripheral Microvascular Resistance as a Predictor for Limb Salvage
    Official Title
    Peripheral Microvascular Resistance as a Predictor for Limb Salvage in Post-Intervention Critical Limb Ischemia Patients
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 15, 2023 (Anticipated)
    Primary Completion Date
    October 15, 2025 (Anticipated)
    Study Completion Date
    October 15, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Hackensack Meridian Health
    Collaborators
    Abbott Medical Devices

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    Yes
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Salvaging a threatened limb is the key therapeutic objective for patients with critical limb ischemia, and the achievement of limb salvage is an independent predictor of patient morbidity and mortality. Despite successful primary endovascular or surgical intervention, the corresponding symptoms of rest pain and/or non-healing ulceration in some patients may continue, and amputation in these patients is unavoidable. It is hypothesized that the functional integrity of the peripheral vascular microcirculation may be impaired in these patients. However, there are currently no techniques that allow direct quantification and visualization of the microcirculation due to the micro-vessel invisibility under angiography. In the coronary circulation, coronary flow reserve (CFR) indicates the capacity for maximal hyperemic blood flow and reveals impaired coronary microvascular function. Studies have shown the clinical significance of measuring microvascular resistance to predict myocardial salvage after myocardial infarction. The study will explore whether this concept of coronary flow reserve can be applied peripherally to patients with critical limb ischemia in order to determine whether measuring peripheral vascular flow reserve can determine the integrity of the microcirculation to predict limb salvage after endovascular intervention.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Peripheral Arterial Disease
    Keywords
    Microvascular disease, Microvascular Resistance, Limb Salvage, Peripheral Arterial Disease, critical limb ischemia

    7. Study Design

    Primary Purpose
    Diagnostic
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    40 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Peripheral vascular flow reserve measurement
    Arm Type
    Experimental
    Arm Description
    Post-procedure peripheral vascular flow reserve by thermodilution will be measured by the pressure wire.
    Intervention Type
    Diagnostic Test
    Intervention Name(s)
    Peripheral vascular flow reserve measurement
    Intervention Description
    Peripheral arterial (below knee popliteal and above the level of ankle distal tibial) thermodilution curves will be obtained. One of the distal tibial arteries (anterior tibial, posterior tibial or peroneal artery, whichever reaches the most distal part of the foot in the run off) will be picked for measurements. At room temperature, 3 ml of saline will be injected brisk manually to determine the peak arterial flow, presented as mean transit time (Tmn). Resting Tmn will be performed and averaged by triplicate measurements at baseline. Then maximal hyperemia will be induced by intra-arterial injection of 30 mg papaverine through the guiding catheter, then 3 ml of saline will be injected to get hyperemic Tmn averaged by triplicate measurements. The guidewire will be kept in a fixed position during the series of measurements. Peripheral vascular flow reserve was calculated as resting Tmn divided by hyperemic Tmn (Fukunaga 2015).
    Primary Outcome Measure Information:
    Title
    Efficacy of the peripheral flow reserve
    Description
    To assess whether peripheral flow reserve can predict the success rate of limb salvage in critical limb ischemia patients after endovascular intervention. Assessed by any amputation (major or minor) at 6 months post-endovascular intervention.
    Time Frame
    6 months post-endovascular intervention
    Secondary Outcome Measure Information:
    Title
    Symptom resolution - Ulcer healing (1m)
    Description
    Ulcer healing: changes in the number and extent of leg ulcers compared to baseline.
    Time Frame
    1 month post-endovascular intervention
    Title
    Symptom resolution - Ulcer healing (6m)
    Description
    Ulcer healing: changes in the number and extent of leg ulcers compared to baseline.
    Time Frame
    6 months post-endovascular intervention
    Title
    Number of patients with Symptom resolution - Pain (1m)
    Description
    Resolution of rest pain and alteration in visual analogue pain compared to baseline.
    Time Frame
    1 month post-endovascular intervention
    Title
    Number of patients with Symptom resolution - Pain (6m)
    Description
    Resolution of rest pain and alteration in visual analogue pain compared to baseline.
    Time Frame
    6 months post-endovascular intervention
    Title
    Ankle-brachial index (ABI) (1m)
    Description
    Improvement in Ankle-brachial index (ABI) compared to baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. Normal ABI ranges from 1.0 - 1.4, with <0.9 suggesting arterial disease.
    Time Frame
    1 month post-endovascular intervention
    Title
    Ankle-brachial index (ABI) (6m)
    Description
    Improvement in Ankle-brachial index (ABI) compared to baseline. The Ankle Brachial Index (ABI) is the systolic pressure at the ankle, divided by the systolic pressure at the arm. Normal ABI ranges from 1.0 - 1.4, with <0.9 suggesting arterial disease.
    Time Frame
    6 months post-endovascular intervention
    Title
    Toe-brachial index (TBI) (1m)
    Description
    Improvement in Toe-brachial index (TBI) compared to baseline. The Toe Brachial Index (TBI) is defined as the ratio between the systolic blood pressure in the right or left toe and the higher of the systolic pressure in the right or left arms. TBI ≥ 0.7 is considered normal while TBI < 0.7 is considered abnormal.
    Time Frame
    1 month post-endovascular intervention
    Title
    Toe-brachial index (TBI) (6m)
    Description
    Improvement in Toe-brachial index (TBI) compared to baseline. The Toe Brachial Index (TBI) is defined as the ratio between the systolic blood pressure in the right or left toe and the higher of the systolic pressure in the right or left arms. TBI ≥ 0.7 is considered normal while TBI < 0.7 is considered abnormal.
    Time Frame
    6 months post-endovascular intervention
    Title
    Rutherford classification (1m)
    Description
    Use of The Rutherford classification to assess peripheral artery disease compared to baseline. A 7 category scale is being used with 0 being Asymptomatic and 6 being Ulceration or gangrene.
    Time Frame
    1 month post-endovascular intervention
    Title
    Rutherford classification (6m)
    Description
    Use of The Rutherford classification to assess peripheral artery disease compared to baseline. A 7 category scale is being used with 0 being Asymptomatic and 6 being Ulceration or gangrene.
    Time Frame
    6 months post-endovascular intervention
    Title
    Transcutaneous oxygen partial pressure (TcPO2) (1m)
    Description
    Transcutaneous partial pressure of oxygen (TcPO2) will be measured representing the amount of oxygen diffusing outward across the skin (used as a surrogate for arterial perfusion).
    Time Frame
    1 month post-endovascular intervention
    Title
    Transcutaneous oxygen partial pressure (TcPO2) (6m)
    Description
    Transcutaneous partial pressure of oxygen (TcPO2) will be measured representing the amount of oxygen diffusing outward across the skin (used as a surrogate for arterial perfusion).
    Time Frame
    6 months post-endovascular intervention
    Title
    Target lesion revascularization (1m)
    Description
    Need for revascularization (yes/no)
    Time Frame
    At 1 month post-endovascular intervention
    Title
    Target lesion revascularization (6m)
    Description
    Need for revascularization (yes/no)
    Time Frame
    At 6 month post-endovascular intervention

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Chronic critical limb ischemia (Rutherford 4-6). Age ≥18 years Ability and willingness to sign the IRB approved Informed Consent form Exclusion Criteria: Non-reconstructable chronic total occlusive disease of the proximal inflow vessels that would make flow reserve measurements impossible. Non-salvageable lower extremity due to infection or overwhelming per-existing tissue loss (most critical Rutherford 6 patients). Inability to understand the study or a history of non-compliance with medical advice; History of any cognitive or mental health status that would interfere with study participation; Currently enrolled in any pre-approval investigational study. Female subjects who are pregnant or nursing or planning to become pregnant within the study period; Known sensitivity to contrast media, which can't be adequately pre-medicated; Expected life span less than 6 months. Unable to read/understand/sign the English Language consent form
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Patricia Arakelian, RN
    Phone
    5519962000
    Ext
    5722
    Email
    patricia.arakelian@hmhn.org
    First Name & Middle Initial & Last Name or Official Title & Degree
    Stephanie Lynes, RN
    Phone
    5519962000
    Ext
    5595
    Email
    Stephanie.Lynes@hmhn.org
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    David O'Connor, MD
    Organizational Affiliation
    Hackensack Meridian Health
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    Citation
    McGinn, A.L., White, C.W. and Wilson, R.F., 1990. Interstudy variability of coronary flow reserve. Influence of heart rate, arterial pressure, and ventricular preload. Circulation, 81(4), pp.1319-1330. Nahser Jr, P.J., Brown, R.E., Oskarsson, H., Winniford, M.D. and Rossen, J.D., 1995. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus. Circulation, 91(3), pp.635-640. Payne, A.R., Berry, C., Doolin, O., McEntegart, M., Petrie, M.C., Lindsay, M.M., Hood, S., Carrick, D., Tzemos, N., Weale, P. and McComb, C., 2012. Microvascular resistance predicts myocardial salvage and infarct characteristics in ST-elevation myocardial infarction. Journal of the American Heart Association, 1(4), p.e002246. Camici, P.G., d'Amati, G. and Rimoldi, O., 2015. Coronary microvascular dysfunction: mechanisms and functional assessment. Nature Reviews Cardiology, 12(1), p.48.
    Results Reference
    background
    PubMed Identifier
    26019143
    Citation
    Fukunaga M, Fujii K, Kawasaki D, Nishimura M, Horimatsu T, Saita T, Miki K, Tamaru H, Imanaka T, Naito Y, Masuyama T. Vascular flow reserve immediately after infrapopliteal intervention as a predictor of wound healing in patients with foot tissue loss. Circ Cardiovasc Interv. 2015 Jun;8(6):e002412. doi: 10.1161/CIRCINTERVENTIONS.115.002412.
    Results Reference
    background
    Citation
    Crea, F., Lanza, G.A. and Camici, P.G., 2014. Mechanisms of coronary microvascular dysfunction. In Coronary Microvascular Dysfunction (pp. 31-47). Springer, Milano.
    Results Reference
    background
    PubMed Identifier
    12034653
    Citation
    Pijls NH, De Bruyne B, Smith L, Aarnoudse W, Barbato E, Bartunek J, Bech GJ, Van De Vosse F. Coronary thermodilution to assess flow reserve: validation in humans. Circulation. 2002 May 28;105(21):2482-6. doi: 10.1161/01.cir.0000017199.09457.3d.
    Results Reference
    background
    PubMed Identifier
    10725297
    Citation
    Kern MJ. Coronary physiology revisited : practical insights from the cardiac catheterization laboratory. Circulation. 2000 Mar 21;101(11):1344-51. doi: 10.1161/01.cir.101.11.1344.
    Results Reference
    background

    Learn more about this trial

    Peripheral Microvascular Resistance as a Predictor for Limb Salvage

    We'll reach out to this number within 24 hrs